Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by HC Wainwright
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” rating to a “neutral” rating in a report issued on Wednesday, MarketBeat reports. The firm currently has a $75.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 27.96% […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” rating to a “neutral” rating in a report issued on Wednesday, MarketBeat reports. The firm currently has a $75.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 27.96% […]
